BTG3 and juvenile idiopathic arthritis: Neither analysis of JIA subgroups with ANA-positive disease with onset before the age of six, treatment with csDMARDs, nor treatment with any DMARD compared to matched references, showed any statistically significant HR (Fig. 1).